Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

10.69 -0.04 (-0.37%)
Streaming Delayed Price Updated: 3:30 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance ↗
Via Chartmill
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones ↗
Prothena reports Q3 2025 earnings, provides updates on its neurodegenerative disease pipeline, and reaffirms strong cash position. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
9 Analysts Assess Prothena Corp: What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of Prothena Corp's Earnings Potential ↗
 
Via Benzinga
News headline image
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
News headline image
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Prothena Corp ↗
 
Via Benzinga
News headline image
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
News headline image
Prothena Q2 Revenue Drops 97% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
8 Analysts Assess Prothena Corp: What You Need To Know ↗
 
Via Benzinga
News headline image
Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast ↗
The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline. 
Via Stocktwits
Topics Workforce
News headline image
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Prothena Stock Trading Lower On Tuesday? ↗
Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and new focus expected. 
Via Benzinga
News headline image
US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert ↗
U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark indices were trading higher in premarket. 
Via Benzinga
Topics Stocks
News headline image
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.